Johnson & Johnson announced a plan to invest more than $1 billion to build a cell therapy manufacturing facility in Pennsylvania as part of a wider effort to scale advanced‑therapy production. The site is intended to support J&J’s growing portfolio of cell and gene therapies and internalize manufacturing capacity amid rising demand for commercial‑scale supply. The investment reflects industry pressure to secure GMP capacity for autologous and allogeneic cell products, reduce supply bottlenecks, and de‑risk commercialization. J&J described the project as a strategic commitment to cell therapy supply chain strength and U.S. manufacturing capability. The move is likely to intensify competition for skilled manufacturing talent and contract capacity while signaling to partners and regulators that large pharmas are investing heavily in end‑to‑end cell therapy commercialization infrastructure.